Page Executive
Chief Medical Officer - Injectable Neurotoxin Aesthetics
Page Executive, Raleigh, North Carolina, United States, 27601
About Our Client
We are partnering with a venture capital-backed biotech developing a next‑generation injectable neurotoxin platform for aesthetic indications. As the company advances into late‑stage development and U.S. regulatory engagement, we are seeking a Chief Medical Officer to lead clinical strategy through FDA approval and support future commercialization.
Key Responsibilities
Lead Phase II/III global clinical trial design and execution for injectable neurotoxin aesthetic indications
Serve as the primary medical interface with the FDA (End‑of‑Phase, pre‑BLA, BLA support)
Define clinical endpoints, safety strategy, and benefit‑risk positioning aligned with regulatory and commercial goals
Build and leverage strong KOL and investigator networks in aesthetics, dermatology, and plastic surgery
Oversee medical affairs strategy, scientific communications, and advisory boards
Partner with CRO and Regulatory, Clinical Ops, Commercial, and BD experts
Present clinical strategy and data to the Board and investors
Qualifications
MD (or equivalent) required
Demonstrated hands‑on leadership of late‑stage clinical programs through FDA approval
Deep experience in injectable aesthetics / neurotoxins or closely related therapeutic areas
Prior senior medical leadership experience (CMO, SVP, VP Clinical/Medical)
Strong FDA engagement experience and credibility with external stakeholders
Established KOL relationships within the U.S. and global aesthetics community
Particularly well‑suited for senior medical leaders from global leading aesthetic‑focused organizations who are ready to take full ownership of an asset and shape its trajectory from late‑stage development to market.
What's on Offer
Executive ownership of a high‑value, differentiated neurotoxin asset
Direct influence on clinical, regulatory, and medical strategy
Meaningful equity upside in a VC‑backed growth platform
Opportunity to transition from large pharma to a high‑impact, decision‑driving CMO role
MPI does not discriminate on the basis of race, religion, sex, sexual orientation, gender identity or expression, age, disability, marital status, or based on an individual's status in any group or class otherwise protected under applicable human rights legislation. MPI encourages applications from minorities, women, the disabled and all other qualified applicants.
If you are ready to take on this exciting Chief Medical Officer role, apply now to join a leading organization in the financial services industry.
#J-18808-Ljbffr
Key Responsibilities
Lead Phase II/III global clinical trial design and execution for injectable neurotoxin aesthetic indications
Serve as the primary medical interface with the FDA (End‑of‑Phase, pre‑BLA, BLA support)
Define clinical endpoints, safety strategy, and benefit‑risk positioning aligned with regulatory and commercial goals
Build and leverage strong KOL and investigator networks in aesthetics, dermatology, and plastic surgery
Oversee medical affairs strategy, scientific communications, and advisory boards
Partner with CRO and Regulatory, Clinical Ops, Commercial, and BD experts
Present clinical strategy and data to the Board and investors
Qualifications
MD (or equivalent) required
Demonstrated hands‑on leadership of late‑stage clinical programs through FDA approval
Deep experience in injectable aesthetics / neurotoxins or closely related therapeutic areas
Prior senior medical leadership experience (CMO, SVP, VP Clinical/Medical)
Strong FDA engagement experience and credibility with external stakeholders
Established KOL relationships within the U.S. and global aesthetics community
Particularly well‑suited for senior medical leaders from global leading aesthetic‑focused organizations who are ready to take full ownership of an asset and shape its trajectory from late‑stage development to market.
What's on Offer
Executive ownership of a high‑value, differentiated neurotoxin asset
Direct influence on clinical, regulatory, and medical strategy
Meaningful equity upside in a VC‑backed growth platform
Opportunity to transition from large pharma to a high‑impact, decision‑driving CMO role
MPI does not discriminate on the basis of race, religion, sex, sexual orientation, gender identity or expression, age, disability, marital status, or based on an individual's status in any group or class otherwise protected under applicable human rights legislation. MPI encourages applications from minorities, women, the disabled and all other qualified applicants.
If you are ready to take on this exciting Chief Medical Officer role, apply now to join a leading organization in the financial services industry.
#J-18808-Ljbffr